INTRODUCTION

It has been demonstrated that Pt
IV diazido complexes which are stable and non-cytotoxic in the dark exhibit significant toxicity in cancer cells upon irradiation with short wavelengths (365 nm) (1) . Their activation with UVA irradiation to produce cytotoxic and reactive Pt II analogues does not require oxygen (1, 2) , an advantage over conventional photosensitizers currently used in photodynamic therapy (PDT), such as those based on tetrapyrrole derivatives. In addition, selective photoactivation of platinum complexes in cancer cells may help to overcome limitations connected with toxic side effects of antitumor platinum drugs currently used in the clinic. The first photoactivatable Pt IV complexes exhibiting toxicity in tumor cells could be photoactivated only upon irradiation with wavelengths in UVA region (1), which is not optimal for clinical applications. Recently, the Pt IV diazido complex trans,trans,trans-[Pt(N 3 ) 2 (OH) 2 (pyridine) 2 ] (1) was synthesized which is both highly soluble and stable in aqueous solution. It can be photoactivated over a range of wavelengths and is toxic towards cancer cells using low doses of UVA radiation and, crucially, also with visible light (3) . The presence of planar pyridine ligands in 1, which appear to remain strongly bound to platinum, even after photoactivation, has a critical effect not only on the photoactivation pathways, but also on the biological activity.
Modification of clinically-ineffective transplatin (trans-[PtCl 2 (NH 3 ) 2 ]) by inclusion of planar ligands
considerably changes the binding mode of the trans-Pt II species with DNA, the major pharmacological target of antitumor platinum complexes (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . These transplatin analogues exhibited promising toxic effects in various human tumor cell lines including those resistant to conventional cisplatin. Thus, photoactivated 1 can be coclustered with other platinum-pyridines which are not cross-resistant and necrotic pathways (22) . Hence, similar to other antitumor platinum-pyridine complexes, the different mechanism of action of photoactivated 1 may also derive from its unique mode of binding to DNA.
To assess the importance of the binding of photoactivated 1 to DNA for the efficacy of its anticancer action, we describe here an investigation of DNA binding of photoactivated 1 in tumor cells treated with this metallodrug under conditions where it is non-toxic towards these cells (in the absence of irradiation). In addition, the fact that photoactivated 1 binds to DNA in cells prompted us to investigate the modifications induced in DNA in vitro (in cell-free media), including conformational alterations of DNA and the processing of these modifications by RNA polymerase II. We believe that a deep understanding of the reactions leading to bifunctional DNA cross-link (CL) formation by photoactivated 1 may provide guidance in future efforts to optimize the rational design of photoactivatable anticancer metallodrugs.
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A2780 cells in 10 cm dishes were treated without or with Pt complexes at the concentration of 24 µM for 1 h in Earle's Balanced Salt Solution (EBSS). After this time, the cells were further kept in the dark or irradiated with UVA for 1 h. Cells were then washed and incubated in the drug-free medium for additional 24 h. At the end of incubation, the floating cells were collected and attached cells were harvested by trypsinization. Total cells (floating + attached) were washed twice in PBS (4 ºC) and lysed in DNAzol (DNAzol® genomic DNA isolation reagent, MRC) supplemented with RNAse A (100 µg mL -1 ). The genomic DNA was precipitated from the lysate with ethanol, dried and resuspended in water.
The DNA content in each sample was determined by UV spectrophotometry. To avoid interference from high DNA concentrations on FAAS detection of platinum in the samples, the DNA samples were digested in the presence of hydrochloric acid (11 M) using an high pressure microwave mineralization system (MARS5, CEM). Experiments were performed in triplicate and the values are the means ±SD.
Platination of DNA in Cell-free Media. If not stated otherwise, CT DNA was mixed with 1 in NaClO 4 (10 mM) and immediately irradiated (UVA, λ max = 365 nm or visible light, λ max = 458 nm) for indicated time and then kept at 37 °C in the dark. The r i value was 0.05 (r i is defined as the molar ratio of free platinum complex to nucleotide phosphates at the onset of incubation with DNA). Aliquots were removed at various time intervals, quickly filtered using a Sephadex G-50 column to remove free (unbound) Pt. The Pt content in these DNA samples (r b , defined as the number of the molecules of platinum complex coordinated per nucleotide residue) was determined by FAAS. where A is the fraction of molecules running as a band corresponding to the non-cross-linked DNA.
DNA Interstrand
Unwinding of Negatively Supercoiled DNA. Unwinding of closed circular supercoiled pUC19 plasmid DNA was assayed by an agarose gel mobility assay (25). The unwinding angle Φ, induced per Pt-DNA adduct was calculated by the determination of the r b value at which the complete transformation of the supercoiled to relaxed form of the plasmid was attained. Samples of pUC19 plasmid were mixed with 1 in NaClO 4 (10 mM ) and irradiated (λ max = 365 nm or λ max = 458 nm) for 1 h.
The samples were then incubated at 37 °C in the dark. After 23 h, all samples were redissolved in the Tris-acetate/EDTA (TAE) buffer and subjected to electrophoresis on 1% agarose gels running at room temperature with TAE buffer and the voltage set at 35 V. The gels were stained with EtBr, followed by photography with a transilluminator. Fluorescence Measurements. These measurements were performed on a Shimadzu RF 40 spectrofluorophotometer using a 1-cm quartz cell. Fluorescence measurements of CT DNA modified by platinum complexes in the presence of EtBr were performed at an excitation wavelength of 546 nm, and the emitted fluorescence was analyzed at 590 nm. The fluorescence intensity was measured at 25 °C in NaCl (0.4 M) to avoid secondary binding of EtBr to DNA (28, 29) . The concentrations were 0.01 mg mL -1 for DNA and 0.04 mg mL -1 for EtBr, which corresponded to the saturation of all sites of EtBr 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 in DNA (29) . Terbium fluorescence measurements were performed by adding TbCl 3 to modified or control DNA (8 µg mL -1 ) at a final concentration equivalent twice the monomeric nucleotide content.
Transcription Mapping of DNA Adducts
The fluorescence intensity was measured after equilibration for 60 min at 25°C in the dark. The excitation and emission wavelengths were 290 nm and 546 nm, respectively. Other details of these measurements can be found in papers published earlier (30) (31) (32) . The gels were then visualized and the radioactivity associated with bands was quantitated. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 mixed with 1 in their equimolar concentrations, irradiated by UVA for 30 min and subsequently incubated in the dark for 24 h. The platinated oligonucleotide was purified by using ionic-exchange HPLC. A product was collected, dialysed against double-distilled water and the unique platinations at the guanine sites were verified by FAAS and DMS footprinting of platinum bound to DNA, as already described (33) . Cisplatin-modified oligonucleotide containing central GG sequence was prepared by the same procedure except for the omission of the irradiation step. The central oligonucletides were than annealed with their bottom strands (69-mers) and two oligonucleotides (two marginal arms, each 23 nt long) were ligated (one to each side) to these duplexes by T4 DNA ligase. Full-length substrates (nonmodified, containing the 1,3-GTG intrastrand CL of photoactivated 1 or the 1,2-GG intrastrand CL of cisplatin) were separated from unligated products on a denaturing 12 % PAA gel, purified by electroelution, reannealed, and stored in NaClO 4 (0.01M).
DNA
Single-lesion
T7 and SP6 RNA Polymerases Reaction on Single-lesion Templates. T7 and SP6 polymerization reactions were performed using Riboprobe® In Vitro Transcription Systems Protocol (Promega, Mannheim, Germany) according the recommended protocol. Briefly, unplatinated or single-lesioncontaining 69 bp templates (2 pmol) were incubated at 37 °C in 20 µL of buffer containing Tris-HCl (40 mM, pH 7.9), NaCl (10 mM), MgCl 2 (6 mM) , DTT (10 mM), spermidine (2 mM), Tween®-20 (0.05%), 0.5 mM each of rATP, rCTP and rUTP, rGTP (0.125 mM) and 0.5µCi [α-32 P]rGTP. The reactions were initiated by the addition of 15 units of T7 polymerase. After 1 h of incubation, reaction mixtures were precipitated by ethanol and resolved by electrophoresis on 12% PAA/8M urea gel. RNA sequencing lanes were generated by adding of 3´-dCTP or 3´-dATP into the reactions containing nonplatinated 69-bp constructs as a template. The reaction with SP6 polymerase was performed as described for T7
polymerase (vide supra) except that the concentration of rGTP was 0.5 mM, rUTP 0.125 mM and 0.5 µCi [α-32 P]rUTP was used.
Other Physical Methods. Absorption spectra were obtained on a Beckman 7400 DU spectrophotometer equipped with a thermostated cell holder. The FAAS measurements were carried out on a Varian AA240Z Zeeman atomic absorption spectrometer equipped with a GTA 120 graphite tube atomizer. The gels were visualized on a BAS 2500 FUJIFILM bioimaging analyzer, and the radioactivity associated with bands was quantified with the AIDA image analyzer software (Raytest, Germany). The first experiments were aimed at quantifying the binding of 1 to mammalian DNA in cell-free media.
Two samples of double-helical CT DNA (32 µg mL -1 ) were incubated with 1 at an r i value of 0.05 in NaClO 4 (10 mM) at 37 °C. The first sample was irradiated with UVA (365 nm, 4.3 mW cm -2 ) or visible (458 nm, 65 mW cm -2 ) light immediately after addition of 1; the other sample was kept in the dark.
Aliquots of both samples were withdrawn at various time intervals; free, unbound platinum was removed by gel filtration through Sephadex G-50 coarse column and DNA was assayed for platinum content by FAAS. Only a very small amount (<5%) of platinum bound to DNA was found in the sample which was kept in the dark, even after a long time of incubation (24 h; Figure 2A ). In contrast, the amount of platinum bound to DNA in irradiated samples increased with time. Under continuous UVA irradiation, 50 % of Pt was bound after 70 min (t 50% ) and the plateau of the platination was reached after 7.5 h continuous irradiation, when nearly 100% of platinum present in the sample was bound to DNA ( Figure 2A) . Similarly, 50 % of Pt was bound after 106 min (t 50% ) and the plateau of the platination reaction was reached after 7.5 h continuous irradiation by visible light, when nearly 70% of platinum present in the sample was bound to DNA ( Figure 2C ). Interestingly, when 1 was first pre-irradiated by UVA for 2 h (in the absence of DNA) and only then added to DNA in the dark, the DNA binding rate was markedly slower and a maximum amount of platinum bound to DNA after 7.5 h was lower as well compared to the situation when 1 was continuously irradiated in the presence of DNA (Figure 2A ).
Unfortunately, extended periods of irradiation in particular by UVA (7.5 h) caused severe DNA damage which made subsequent analysis of conformational properties of DNA modified by photoactivated 1 impossible. Therefore, other modes of irradiation were also tested (shown for UVA irradiation in Figure 2B ). DNA was mixed with 1 at r i = 0.05, samples were pre-irradiated for a preselected time (0.5, 1 or 2 h) and subsequently incubated in the dark. Aliquots were withdrawn and DNA was assayed for platinum content as described above. Figure 2B shows that the total amount of platinum bound to DNA after 24 h of post-irradiation incubation increases with the length of the preirradiation (in the presence of DNA). As mentioned above, when 1 was first irradiated for 2 h in the absence of DNA, then added to DNA and the sample was subsequently incubated in the dark, the amount of platinum bound to DNA was considerably lower than that when 1 was irradiated for 2 h in the presence of DNA and the sample was subsequently incubated in the dark (cf. Figures 2A and B) .
Qualitatively similar results were obtained if 1 or the mixtures of DNA with 1 were pre-irradiated with visible light, although yields of DNA binding reactions were lower compared to those when the mixtures were pre-irradiated by UVA.
Thus, these DNA binding experiments ( Figure 2 ) clearly indicated that 1 was inactive and unable to bind DNA in the dark, but under irradiation by UVA or visible light it became active and strongly bound DNA. The results of these DNA binding studies in cell-free media indicate that the rates of binding to aliquot of this sample was checked by FAAS. In this way, the analyses described in the present paper were performed in the absence of unbound (free) platinum complex if not stated otherwise.
Characterization of DNA Adducts of Photoactivated 1 with Thiourea. Cisplatin, transplatin, and analogues of these bifunctional platinum compounds coordinate to DNA in a two-step process, forming first monofunctional adducts preferentially at guanine residues; these monofunctional adducts subsequently close to bifunctional lesions (35, 36) . Considerable evidence suggests that monofunctionally-bound transplatin and its analogs are labilized by thiourea, whereas bifunctional adducts are resistant (37, 38) . TU is used to labilize monofunctionally bound transplatin and its analogues from DNA (37) . The displacement of transplatin or its analogues is initiated by coordination of TU trans to the nucleobase. Owing to the strong trans effect of sulfur, the nucleobase nitrogenplatinum bond is weakened and thus becomes susceptible to further substitution reactions.
Consequently, transplatin or its analogues in monofunctional DNA adducts are effectively removed, whereas bifunctional adducts of transplatin or its analogues are resistant to TU treatment (37) . The experiments aimed at the characterization of DNA adducts of photoactivated 1 were conducted employing TU as a probe for DNA monofunctional adducts formed by this trans-platinum compound.
Double-stranded CT DNA was mixed with 1 at a drug-to-nucleotide ratio of r i = 0.05 in NaClO 4 (10 mM), irradiated for 1 h by UVA or visible light and then incubated in the dark for an additional 23 h.
During this period the platination reaction was stopped at various time intervals by addition of NaCl photoactivated 1 in pSP73KB plasmid (2455 bp). This plasmid DNA was linearized by EcoRI (EcoRI cuts only once within pSP73KB plasmid) and radioactively labeled on its 3´-end.
Plasmid DNA was incubated with 1 at varying concentrations, irradiated for 1 h by UVA or visible light and incubated in the dark for an additional 23 h. The samples were then analyzed for interstrand
CLs by agarose gel electrophoresis under denaturing conditions (39) . Upon electrophoresis, 3'-end labeled strands of linearized pSP73KB plasmid containing no interstrand CLs migrate as a 2455-base single strand, whereas the interstrand cross-linked strands migrate more slowly as a higher molecular mass species (Figure 4 ). The intensity of the more slowly migrating DNA fraction increased with the growing level of the platination. The radioactivity associated with the individual bands in each lane was measured to obtain estimates of the fraction of noncross-linked or cross-linked DNA under each condition. The frequency of interstrand CLs of photoactivated 1 was calculated as described earlier (38) and was found to be 12 ± 2% (mean and standard deviation calculated from three independent experiments) for DNA modified by 1 photoactivated by both UVA and visible light. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 results. It was verified that irradiation of CT DNA by UVA or visible light in the absence of 1 for 5 h had no effect on EtBr fluorescence. (31, 32) . This assay is based on the observation that Tb 3+ fluorescence is strongly enhanced when the ion is bound to the phosphate moieties of G residues in distorted DNA regions (30) (31) (32) . The modification of double-helical DNA by cisplatin has been shown to result in substantially increased fluorescence of the lanthanide cation, which binds to unplatinated G residues in distorted regions around the platination site (31, 32) . In contrast, coordination of complexes such as clinically ineffective transplatin or monofunctional [PtCl(dien)]Cl to doublestranded DNA does not result in distortions of the helix structure that would affect terbium fluorescence (31, 32) . h had no effect on terbium fluorescence. Transcription of DNA Modified by Photoactivated 1 by RNA Polymerase II In Vitro. One of the key factors that is important for platinum drug-mediated cytotoxicity is the arrest of RNA synthesis by Pt-DNA CLs (21). Therefore, the ability of 1 to affect transcription activity of human RNA polymerase II (RNA pol II) was tested using HeLaScribe1 Nuclear Extract in vitro Transcription system kit. Using an analogous procedure as described earlier (41) As seen in Figure 8A , in the absence of platination, a high level of full length transcript was observed. In contrast, a significant decrease in the amount of full-length transcript was observed as a result of increasing template modification by 1 photoactivated by both UVA and visible light ( Figure   9A ). The relative amount of full-length transcript generated from each reaction was quantitated and plotted as a function of the level of the template platination (r b ) ( Figure 9B ). The results obtained for DNA modified by cisplatin in the dark under identical conditions were also included for comparative purposes. Under the conditions employed, RNA pol II transcription was highly sensitive to even very low levels of platinum damage on the template DNA, the damage by photoactivated 1 being more effective in inhibiting RNA pol II transcription compared to cisplatin.
Unwinding of Negatively
To investigate the possibility that RNA pol II catalytic activity was inhibited as a consequence of hijacking factors essential for RNA pol II initiation by DNA adducts of photoactivated 1 (41), the following competition experiments were performed. RNA pol II transcription of undamaged template pCMV-Gluc was examined in the presence of increasing levels of a second, exogenous pUC19 plasmid containing multiple lesions caused by either photoactivated 1 or cisplatin. As shown in Figure 8C , the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 initial addition of control, undamaged exogenous plasmid resulted in an overall increase in the amount of transcript generated by pCMV-Gluc which only slightly increased upon the further addition of unplatinated plasmid. RNA pol II transcription of pCMV-Gluc template was significantly reduced by the addition of increasing amounts of cisplatin modified exogenous plasmid. In contrast, a negligible inhibition effect was seen if the transcription assay was performed in the presence of exogenous plasmid containing adducts of 1 photoactivated by UV or visible light (shown in Figure 8C for DNA modified by 1 photoactivated by UVA). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 prior to the adduct site and at the first platinated guanine ( Figure 9B ). Transcription by T7 RNA polymerase from the unplatinated GG construct templates yielded similar results to those of the unplatinated GTG template ( Figure 9B ). The 1,2-GG intrastrand CL of cisplatin was also a block to the progression to the T7 RNA polymerase, displaying a blockage pattern different from that of the GTG adduct of photoactivated 1. T7 RNA polymerase was blocked mainly at the sites of the adducts (one half prior to the first and second platinated guanine). In this case, the full length product was also observed, although the intensity of this fraction was markedly reduced compared to the unmodified template. From the intensity of the T7 RNA polymerase blockage sites relative to the intensity of the full-length transcript, it can be calculated (taking into account the relative number of radiolabeled nucleotides incorporated into the RNA) that there were 73% and 100% blockages by the major adducts formed by cisplatin and photoactivated 1, respectively.
Effect of the
The effect of the GTG-adduct formed by photoactivated 1 (in the top strand) on transcription of the bottom, unplatinated strand was also tested using the same constructs. SP6 RNA polymerase was employed which transcribed the bottom, unplatinated strand of the constructs ( Figure 9B , right panel).
The presence of adducts of both cisplatin and photoactivated 1 in the top strand of the construct had no effect on the ability of SP6 RNA polymerase to transcribe the bottom, unplatinated strand and synthesize full length products. 
DISCUSSION
The cytotoxic effects of antitumor platinum drugs might arise from a number of mechanisms, including tumor cell accumulation, protein interacions, DNA modifications and their cellular processing (34, 43, 44) . To support the view that DNA is a potential target for photoactivated 1, platinum levels on nuclear DNA were determined after exposure of A2780 tumor cells to 1 photoactivated by UVA.
Measurements of DNA-bound platinum after exposure to the photoactivatable platinum drug under irradiation revealed that the amount of platination by 1 was markedly (~16-fold) higher compared to that determined after the treatment with the same dose of cisplatin in dark for the same time. Importantly, no Pt bound to DNA was observed if the cells were treated with 1 in the dark. These results confirm that 1 when photoactivated accumulates in tumor cells, penetrates the nucleus and binds strongly to nuclear DNA under conditions in which it exhibits cytotoxicity. This suggests that penetrating the nucleus and binding to nuclear DNA may provide an important contribution to the mechanism of cytotoxicity of photoactivated 1. DNA may therefore be a potential target for this cytotoxic photoactivatable platinum complex, although we cannot rule out the possibility that nuclear DNA may not be the only target. In other words, toxic effects of 1 in tumor cells may be associated with processes at the DNA level.
The finding that the photoactivated 1 is capable of delivering platinum to DNA in the cell nucleus prompted us to examine the binding of 1 to DNA in a cell-free medium. The resulting DNA damage triggers downstream effects including inhibition of replication and transcription, cell cycle arrest, and apoptosis or necrosis (22, 45, 46) . The results of these studies were compared with those previously performed with conventional cisplatin and transplatin.
The CT DNA binding experiments carried out in the present work in a cell-free medium indicated that modification reactions resulting in the irreversible coordination of photoactivated 1 were faster than those of cisplatin or transplatin (Table 1) . Platinum binding to CT DNA resulting from treatment of DNA with 1 preirradiated for 2 h in the absence of DNA was significantly lower than that resulting from treatment of DNA when 1 was preirradiated for 2 h in the presence of DNA (cf. Figures 2A and 2B ). This observation suggests that free 1 can be transformed into highly reactive species that can be trapped by DNA if it is present in the same solution, whereas photoproducts formed in the absence of DNA become less reactive towards it. Table 1) and ca. 37% of DNA adducts remain monofunctional even after 24 h ( Figure 3 , Table 1 ). The remaining lesions are intrastrand adducts, presumably 1,3-CLs. Thus, it is reasonable to suggest that several aspects of DNA binding mode of photoactivated 1 are similar to those of conventional transplatin (in the dark) (Table 1) . On the other hand, it cannot be excluded that identical types of DNA adducts of Electrophoresis in native agarose gel was used to determine the unwinding induced in negatively supercoiled plasmid by monitoring the degree of supercoiling ( Figure 5 ). The unwinding angle calculated in this way for 1 photoactivated by UVA or visible light was similar, 28 ± 3° or 27 ± 3°, respectively. This unwinding angle is considerably greater than that found for cisplatin or transplatin (13° and 9°, respectively, Table 1 ). It is reasonable to suggest that the large additional contribution to unwinding is associated with interaction of yhe pyridine ligand(s) in photoactivated 1 with the duplex. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 effects (20, [51] [52] [53] [54] . This important component of the mechanism underlying the antitumor effects of platinum drugs has not been hitherto investigated in the case of photoactivatable platinum compounds.
Adducts such as trans-[Pt(py)
We demonstrate in the present work for the first time (Figure 8 ) that RNA pol II transcription is highly sensitive to even very low levels of modification on the template DNA by photoactivated 1. Thus, already very low levels of DNA modification by photoactivated 1 may initiate transcription-coupled subpathways leading to apoptosis or necrosis (55).
Importantly, adducts of photoactivated 1 are markedly more effective in inhibiting RNA pol II transcription than those of conventional cisplatin ( Figures 8B and 9 ). This different reduction in transcript production may result from a different level of platination and/or conformational distortions at the promoter, leading to promoter inactivation. The inhibition effects were observed, however, at levels We examined in the present work whether some elements of the transcription complex might be hijacked by DNA adducts of photoactivated 1 more or less than by those of cisplatin using a competition assay (41) ( Figure 8C ). The initial addition of control, unplatinated exogenous pUC19 plasmid resulted in an overall increase in the amount of transcript generated by pCMV-Gluc substrate, which increased only slightly upon the further addition of unplatinated exogenous plasmid. Such an increase in transcription efficiency has been already reported (41) and was attributed to an increase in macromolecular crowding induced by the presence of higher amounts of DNA (41, 56) . We observed in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the present work ( Figure 8C ), in accord with the previously published results (40, 41) , that RNA pol II transcription of the pCMV-Gluc template was markedly reduced by the addition of increasing amounts of cisplatin-modified exogenous plasmid ( Figure 8C ). Thus, these results are consistent with and support the 'hijacking' hypothesis raised earlier for mononuclear Pt II drugs (41, 44, 57, 58) that RNA pol II transcription of template modified by cisplatin is inhibited to a substantial extent due to the transfer of some elements of the transcription complex away from their normal binding sites and in this way interfer with transcription.
A markedly lower inhibition effect was seen if the transcription assay was performed in the presence of exogenous plasmid modified by photoactivated 1 ( Figure 8C) . Thus, the stronger inhibition of transcription by DNA adducts of photoactivated 1 appears to be due to pronouncedly more extensive steric blockade of RNA pol II inhibiting the prolongation of RNA transcript and not due to sequestration of elements of the transcription complex to platinated sites in DNA. Thus, this study has revealed that the cause of the stalling of RNA pol II by DNA adducts of photoactivated 1 and cisplatin during transcription is apparently distinctly different providing a basis for a different mechanism of action for photoactivated 1 and cisplatin.
The observation in the present work that transcription elongation by RNA pol II was inhibited by titrating some elements of transcription complex away from their normal binding sites much more by DNA adducts of cisplatin than by those of photoactivated 1 ( Figure 8C ) deserves further discussion.
Many transcription factors are HMG-domain proteins (HMG = high mobility group). These proteins have been shown to recognize and bind with a strong affinity to structural motifs in DNA that involve directional rigid bends of the longitudinal axis of this double-helical nucleic acid. Major DNA adducts of cisplatin (intrastrand CLs between neighboring purine residues which represent ~90% of all DNA adducts of cisplatin (16)) produce in DNA a stable directional curvature (~40° toward major groove of DNA) (44, 59). Therefore, this bending apparently represents an important structural motif responsible for a high affinity of many transcription factors to DNA modified by cisplatin. In contrast, DNA adducts of photoactivated 1 (presumably similar to those formed by conventional transplatin, i.e. mainly 1,3-Page 27 of 48
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In 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
AUTHOR INFORMATION
Corresponding Author *Tel: +420 541517174. Fax: +420-541240499. E-mail: jana@ibp.cz.
Funding Sources
This work was supported by the Czech Science Foundation (Grants P301/10/0598 and 301/09/H004).
Research of JP was also supported by the student project of the Palacky University Olomouc (Grant PrF 2012 026). NF and PJS thank the EPSRC (EP/G006792/1) and the ERC (award no 247450) for funding.
ACKNOWLEDGEMENT
We thank members of EC COST Action D39 for stiumulating discussions. 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the dark for additional 23 h) at various r i values in NaClO 4 (10 mM ) at 37 °C. Autoradiogram of denaturing 1% agarose gel of linearized DNA which was 3'-end labeled and nonmodified (lanes 1,2 and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 template (incubated in the dark for 24 h); C(UVA), control, nonplatinated template irradiated by UVA It was verified that irradiation of CT DNA by UVA or visible light in the absence of 1 had no effect on EtBr or terbium fluorescence. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 cisplatin at r b = 8 x 10 -4 , 1.6 x 10 -3 and 3.2 x 10 -3 , respectively; 6,7, and 8, pCMV-Gluc substrate 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Figure 5 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Figure 9
Page 48 of 48
ACS Paragon Plus Environment
Chemical Research in Toxicology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
